Stock IDYA IDEAYA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Market Closed - Nasdaq
Other stock markets
 01:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
36.12 USD -2.38% Intraday chart for IDEAYA Biosciences, Inc. -3.09% +1.52%
25/06 IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer CI
24/06 IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
PR
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
PR
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR
IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
PR
IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
PR
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
PR
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4) - April 26, 2024
AQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
AQ
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
PR
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
PR
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA in Patients with Endometrial Cancer
AQ
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
PR
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
PR
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
PR
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
PR
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IDYA Stock
  4. News IDEAYA Biosciences, Inc.
  5. Press Releases